Seroatlas · Human Serome Atlas

AZI2

5-azacytidine-induced protein 2

Also known as: AZ2, AZI2_HUMAN, FLJ21939, NAP1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9H6S1
Gene: AZI2
Ensembl: ENSG00000163512
Chromosome: 3
Canonical length: 392 aa
Protein class: Predicted intracellular proteins
Quaternary structure: Homodimer

OverviewNCBI Gene

AZI2, or NAP1, contributes to the activation of NFKB (see MIM 164011)-dependent gene expression by activating IKK-related kinases, such as NAK (TBK1; MIM 604834) (Fujita et al., 2003 [PubMed 14560022]).[supplied by OMIM, Mar 2008]

Canonical amino-acid sequenceUniProt

392 residues, UniProt reviewed canonical sequence.

>Q9H6S1|AZI2
     1  MDALVEDDIC ILNHEKAHKR DTVTPVSIYS GDESVASHFA LVTAYEDIKK RLKDSEKENS
    61  LLKKRIRFLE EKLIARFEEE TSSVGREQVN KAYHAYREVC IDRDNLKSKL DKMNKDNSES
   121  LKVLNEQLQS KEVELLQLRT EVETQQVMRN LNPPSSNWEV EKLSCDLKIH GLEQELELMR
   181  KECSDLKIEL QKAKQTDPYQ EDNLKSRDLQ KLSISSDNMQ HAYWELKREM SNLHLVTQVQ
   241  AELLRKLKTS TAIKKACAPV GCSEDLGRDS TKLHLMNFTA TYTRHPPLLP NGKALCHTTS
   301  SPLPGDVKVL SEKAILQSWT DNERSIPNDG TCFQEHSSYG RNSLEDNSWV FPSPPKSSET
   361  AFGETKTKTL PLPNLPPLHY LDQHNQNCLY KN

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AZI2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.6
Highest tissue expression: 25 nTPM

Expression across tissuesHPA

Tissue

adipose tissue: 25 nTPM
bone marrow: 20 nTPM
cerebral cortex: 18 nTPM
salivary gland: 17 nTPM
hypothalamus: 16 nTPM
testis: 15 nTPM

Single-cell type

neutrophil progenitors: 242 nCPM
neutrophils: 235 nCPM
esophageal apical cells: 141 nCPM
somatotrophs: 134 nCPM
monocytes: 112 nCPM
epididymal principal cells: 107 nCPM

Immune cell

basophil: 75 nTPM
classical monocyte: 38 nTPM
intermediate monocyte: 31 nTPM
non-classical monocyte: 28 nTPM
eosinophil: 26 nTPM
total PBMC: 19 nTPM

Brain region

hypothalamus: 28 nTPM
thalamus: 27 nTPM
choroid plexus: 27 nTPM
pons: 25 nTPM
cerebellum: 24 nTPM
basal ganglia: 24 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.69
gnomAD pLI: 0.01
gnomAD missense Z: 0.7
DepMap mean gene effect: 0.05
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of AZI2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AZI2 as an antibody target. Whether an autoantibody or antibody against AZI2 could matter depends on whether native AZI2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AZI2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label AZI2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...